Labels for remicade and humira have been

(Reuters) - U.S. health regulators have received more reports of a rare form of blood cancer in young patients taking anti-inflammatory class of drugs used to treat digestive disorders lasix 60 mg. Drugs called tumor necrosis factor (TNF)-blockers used to treat Crohn's disease and ulcerative colitis, which cause inflammation of the digestive system. These include such widely used products such as Merck Co Inc and Johnson Johnson Remicade and Simponi, Amgen Inc Enbrel, in Humira Abbott Laboratories Inc and Cimzia UCB SA. Food and Drug Administration earlier warned about increased risk of lymphoma and other cancers associated with TNF blockers in children and adolescents. In its report on Thursday, FDA said that blood cancer known as Hepatosplenic T-cell lymphoma or HSTCL, reported mainly in adolescents and young people who took TNF blockers and other drugs such as azathioprine, which also suppresses the immune system and mercaptopurine, leukemia drugs. Labels for Remicade and Humira have been updated and labels for azathioprine and mercaptopurine have been updated to include warnings about HSTCL, FDA said on its website.

Most cases were in patients treated with Crohn's disease or ulcerative colitis, FDA said, but reports also included patients treated with psoriasis and two patients treated rheumatoid arthritis. TNF blockers suppress the immune system by blocking the activity of TNF (tumor necrosis factor), a substance in the body that cause inflammation and lead to immune system diseases. .